SCHEMBL21485559

SCHEMBL21485559

CC1CC2(C1)CC(NC(=O)c1ccc(F)c3ccn(Cc4ccc(-c5cccc(F)c5)cc4)c13)C2

nearest known ligand 0.42

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 9/20 0.42
▸ CNR1 P21554 7/20 0.42
▸ DRD2 P14416 1/20 0.42
▸ DRD4 P21917 1/20 0.42
▸ GRM2 Q14416 1/20 0.38
▸ MAP4K4 O95819 5/20 0.38
▸ ICMT O60725 2/20 0.37
▸ BRD4 O60885 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21481826 0.92 CNR2 (0.43) CNR2CNR1
SCHEMBL21458193 0.91 DRD2 (0.43) CNR2CNR1DRD2DRD4MAP4K4
SCHEMBL31203411 0.91 CNR2 (0.44) CNR2CNR1DRD2DRD4MAP4K4
SCHEMBL21481829 0.90 CNR1 (0.42) CNR2CNR1DRD4GRM2BRD4
SCHEMBL21481771 0.90 MCHR1 (0.45) CNR2CNR1BRD4
SCHEMBL21481778 0.88 CNR1 (0.40) CNR2CNR1
SCHEMBL21506748 0.87 CNR2 (0.40) CNR2CNR1BRD4
SCHEMBL21482094 0.87 NAAA (0.43) CNR2CNR1
SCHEMBL21485555 0.86 CNR2 (0.47) CNR2CNR1DRD4BRD4
SCHEMBL21506622 0.86 CNR2 (0.54) CNR2CNR1DRD2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 — — US disclosed
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2023-02-09 — — US disclosed
US-10968201-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2021-04-06 — — US disclosed
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2021-01-28 — — US disclosed
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2019-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795156-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 CNR2 3/4885CNR1 6/4885DRD2 918/4885
US-10968201-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 CNR2 3/4885CNR1 6/4885DRD2 918/4885
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CNR2 3/4885CNR1 6/4885DRD2 918/4885
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CNR2 3/4885CNR1 6/4885DRD2 918/4885
US-20190315712-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 CNR2 3/4885CNR1 6/4885DRD2 918/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback